Revolutionizing the Market Insight Report offerings valuable across the product lifecycle
Offer best-in-industry knowledge solutions & insights to transform the healthcare world
Enable clients to unlock the value potential for their assets
Cutting edge solution, robust analytics, and valuable insights empower evidence-based decision-making
Our Pillars

Strategy Products
- Epilansis
- PayerPro360
- Analogue tool for market forecasts

Primary market research services
- Physician/KOL interviews
- Payer interviews
- Physician surverys
- Payer surveys

Reports & Insights
- Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
- Epidemiology Insights
- Current Treatment Insights
- Emerging Therapy, Unmet Needs and TPP Insights
- Market Access and Reimbursement Insights

Consulting Services
- Therapy Area/Disease Area Strategy
- Opportunity assessment
- Market sizing and forecasting
- Competitive intelligence
- Indication/Asset Prioritization
- Portfolio Optimization
- Target Product Profile Analysis
- Market Access and Pricing
- Conference Coverage
- In-licensing / Outlicensing Studies
What’s new
Reports and Insights
Market Outlook and Forecast
Thelansis’s “Cardiac Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cardiac Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Unresectable Hepatocellular Carcinoma (uHCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Unresectable Hepatocellular Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Metastatic Synovial Sarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Synovial Sarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Moderate to Severe Acute Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Acute Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Systemic Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Systemic Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Clients form the core of our values, and we strive to maintain the reputation of a ‘Valued Knowledge Partner’

24×7 Online Support
Integration of Thelansis Global support team across continents offers support round the clock for all locations, no matter which region or country you are in.

Interactive Platform
Our multiple report offerings are available on an interactive web-based platform to quickly filter and analyze relevant data.

Customized Offerings
We often customize our syndicated report content to suit client needs.
Years Experience
Experts
Physicians in Panel
Payers in Panel
Global Delivery Centers
Delivered Market Outlook Reports in 2024
Client Reviews
Hear from happy customers about their experience working with us.
“Support on current drug utilizations and benchmarking of emerging therapy, greatly helped us in narrowing down on patient share estimations for internal calculations ״
Santen PharmaDirector
“Patient share for approved therapies are estimated perfectly. Indeed it's great pieces of work. I liked the way segmentation was shown and patient flow was discussed״
Vicore PharmaDirector
“Happy to read the market insight report, really informative and applied to build marketing strategy״
NewronDirector
“This is the first time I worked with Thelansis, I could say the team is truly professional, Cheers guys ״
SanquinDirector
“ We want to congratulate team Thelansis for their continuous support during this tough time ״
WEX TherapeuticsDirector
"We are really fortunate to interact with Thelansis' Forecasting team, well seasoned professionals who understand what's the actual need "
Reata PharmaceuticalsVice President
" We are really fortunate to interact with Thelansis' Forecasting team, well seasoned professionals who understand what's the actual need "
Stemline TherapeuticsVice President- Marketing
"Some great piece of patient based forecast model; and market assumptions. Tying up beautifully with the payer's insights "
CamurusDirector
"Liked the way the outcome was structured. Regulatory assessment was spot-on. Country-wise regulatory scenarios were gold to us at this point"
Asarina PharmaDirector
"Satisfied with the companies core competency around Clinical Trial Outcome analysi"
Acadia PharmaceuticalsDirector

Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.